Financials

  • Market Capitalization 3.1 B
  • Employee 339
  • Founded 2016
  • CEO N/A
  • Website www.veratx.com
  • Headquarter Delaware, United States
  • FIGI BBG00Q72WYG3
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-7.26
ratio cours/chiffre d'affaires
-2 982.67

Related tickers

#NomPrix24h %7 jours %1M %1 an %Cap Boursière7 Derniers Jours
1672
RARE
Ultragenyx Pharmaceutical Inc. - Common Stock
32.03 USD-3.58%-9.11%+25.41%+16.94%3.15 B USD
1673
ELVN
Enliven Therapeutics, Inc. - Common Stock
51.73 USD+1.69%+2.76%+21.69%+150.39%3.15 B USD
1710
CLDX
Celldex Therapeutics, Inc. - Common Stock
38.17 USD-0.93%-3.37%+20.37%+40.12%3.00 B USD
1758
IRON
Disc Medicine, Inc. - Common Stock
75.01 USD-1.28%-4.80%+8.62%+29.35%2.87 B USD

Nouvelles